AstraZeneca, and its global biologics research and development arm MedImmune, have announced a new multi-term agreement with Innate Pharma, building on an existing collaboration, aimed at accelerating each company’s oncology
AstraZeneca and Merck & Co. have announced detailed results from the Phase III SOLO-1 trial testing Lynparza (olaparib) tablets as a maintenance treatment for patients with newly-diagnosed, advanced BRCA-mutated (BRCAm)
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
Nordic Life Science
The latest clinical trials
The company announces results from their BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who
Moberg Pharma has completed the recruitment of 365 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal
Ozempic consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (i.e. adverse cardiovascular events, MACE) in people
Professor Jan Nilsson’s research team at Lund University has received an additional DKK 1,000,000 funding from the Novo Nordisk Foundation for carrying out preclinical studies for Follicum’s diabetes project based on
Acarix announces that two Swedish hospitals – Kristianstad and Sunderbyn – have evaluated the CADScor System for rule-out of Coronary Artery Disease. The evaluation compares favorably against existing methods and
AstraZeneca and MedImmune have announced new results from their TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet
AstraZeneca has announced results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). In the trial, Bevespi Aerosphere demonstrated non-inferiority
The Swedish company has announced the results of a preclinical study confirming the potential for its NanoZolid technology for use with STING agonists, a novel cancer immunotherapy treatment. Due to
The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial.
The latest research news from the Nordic region
Scientists from the University of Turku have discovered a link between certain genetic mutations, the aggressiveness of prostate cancer, risk of developing the disease and poorer survival rates of patients.
Researchers at Karolinska Institutet have discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. Already over 40 years ago
Professor Lorelei Lingard’s research has contributed significantly to our understanding of how healthcare professionals interact and communicate with each other, which has led to new clinical practices and increased patient
Medical or surgical treatment of severe heartburn prevents cancer of the oesophagus, a study from Karolinska Institutet with almost one million Nordic patients reveals. The results are published in the
The Swedish national government gives clearance to the detailed plan for Science Village at the European Spallation Source (ESS) in Brunnshög, Lund. The Swedish Radiation Safety Authority’s study has given answers
Just before summer, the last piece of the puzzle in the building of the new Campus Flemingsberg, was inauguarated, forming a new hub of biomedical research in the Stockholm region.